Described herein is a composition and method of treating COVID-19 with lipid-peptide fusion antiviral therapy. Also described is a composition and method of treating Ebola with lipid-peptide fusion antiviral therapy.

The disclosure relates to defective interfering genes and viruses thereof. It has been discovered that defective interfering genes designed from influenza and coronavirus species can inhibit infection or replication of the parent virus. In vivo, DIGs induce rapid-onset prophylactic protection of infected animals against lethal viral doses. Thus, disclosed herein are nucleic acids containing DIGs, pharmaceutical compositions thereof and associated methods of use. For example, described herein is an isolated polynucleotide containing one or more defective interfering genes, wherein each of the one or more defective interfering genes contains a nucleotide sequence corresponding to one or more portions of an influenza or coronavirus gene or genome, wherein the nucleotide sequence includes a deletion in the gene. The DIGs can be in the form of a plasmid. Pharmaceutical compositions of the plasmid can be used to limit viral replication and prevent or treat influenza or coronavirus associated diseases.

Described herein is the use of thin film freeze drying methods with oil-in-water adjuvants to produce improved vaccine compositions. This approach solves several major problems associated with the emulsion-adjuvanted vaccines. Additionally, the developed dry powder compositions have the potential to be administered via non-invasive routes (such as intranasal, pulmonary, transcutaneous with or without microneedles) and be stored at ambient temperatures which significantly reduce the costs of vaccination programs.

A suprastructure comprising a modified influenza hemagglutinin (HA) is provided. The modified HA may comprise one or more than one alteration that reduces non-cognate binding of the modified HA to sialic acid (SA) on the surface of a cell, while maintaining cognate interaction with the cell, such as a B cell. A composition comprising the suprastructure and modified HA and a pharmaceutically acceptable carrier is also described. A method of increasing an immunological response or inducing immunity in response to a vaccine comprising the suprastructure and modified HA is also provided.

The present disclosure provides a recombinant herpesvirus of turkeys (HVT) and a preparation method and use thereof. The present disclosure specifically provides a recombinant HVT, where an exogenous gene is inserted in a spacer region between an HVT005 region and an HVT006 region of an HVT genome; and the exogenous gene is selected from a gene derived from the group consisting of a Newcastle disease virus (NDV), an avian influenza virus (AIV), and an infectious bursal disease virus (IBDV); the spacer region between an HVT005 region and an HVT006 region of an HVT genome is located between 8,867 nt and 9,319 nt of the HVT genome, and has a nucleotide sequence set forth in SEQ ID NO: 1.

The invention provides an aqueous acidic formulation suitable for use as in the preparation of a pharmaceutically acceptable fluorocarbon-linked peptide formulation, which aqueous formulation comprises a first fluorocarbon-linked peptide, wherein: the peptide linked to the fluorocarbon is at least 20 amino acid residues long, comprises at least 50% hydrophobic amino acid residues and has an isoelectric point greater than or equal to 7; and the fluorocarbon-linked peptide is present in micelles.

Disclosed is a Toxoplasma gondii cyst wall protein cst1 (CST1)-containing influenza virus-like particle, which includes a core consisting of an influenza virus matrix protein 1 (M1); and the CST1 protein of Toxoplasma gondii displayed on a surface thereof; and a vaccine using the same.

Disclosed are a novel coronavirus vaccine based on an influenza virus vector and a preparation method thereof. The vaccine can efficiently express two antigens, i.e., its own HA antigen and an exogenous SC2R1 antigen, enabling the vaccine to induce immune responses to the two antigens, thus achieving the purpose of preventing both influenza virus and novel coronavirus, thereby eliminating the impacts of the two major infectious diseases of influenza and novel coronavirus on social economy, etc. at one time. In addition, based on existing mature influenza platform techniques, the influenza vaccine can be prepared and produced on a large scale, and the use of influenza vaccines has a long history and good safety.

The invention is directed to portions of proteins of gram-positive bacteria, gram-negative, acid-fast bacteria (Mycobacteria, Staphylococcus) and/or virus (SARS-COV-2, Influenza), and antibodies reactive against these portions that can be formulated as immunogenic compositions and vaccines for the treatment and prevention of a microbial and/or viral infections. Preferably, compositions of the invention contain one or more portions of selected microbial and/or viral proteins that, upon administration to a subject, generate an effective cellular and/or humoral immune response, modulate immunity and a cytokine response. Effective responses involve an increased generation of antibodies that enhance immunity against an infection and promote an enhanced a phagocytic response. Monoclonal antibodies produced against these peptides enhance phagocytosis and killing of bacteria, viruses, and other microbes by phagocytic cells, and enhance clearance from the blood.

Provided herein are influenza hemagglutinin stem domain polypeptides, compositions comprising the same, vaccines comprising the same and methods of their use.